Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PARP1 | P09874 | 2/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332757 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL13858810 | 0.86 | KDM4E (0.66) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL17444767 | 0.82 | KDM4E (0.73) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL6340069 | 0.82 | BRD4 (0.75) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL17444764 | 0.81 | TDP1 (0.57) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL17444766 | 0.78 | KDM4E (0.60) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL17444768 | 0.77 | AR (0.64) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL17444762 | 0.76 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL17444769 | 0.76 | KDM4E (0.57) | SMN1; SMN2KDM4EPOLBBRD4LMNA | |
| SCHEMBL9328808 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EPOLBLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677799-A4 | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
| EP-1677799-A1 | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | Merck & Co., Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005041971-A1 | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | PER2, CNR2, OPRD1 | SMN1; SMN2 2442/4885KDM4E 1349/4885POLB 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.